Retinopathy of Prematurity (ROP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Retinopathy of Prematurity (ROP) Market Outlook
Thelansis’s “Retinopathy of
Prematurity (ROP) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Retinopathy
of Prematurity (ROP) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Retinopathy
of Prematurity (ROP) Overview
Retinopathy
of prematurity (ROP) is an eye disease that affects some premature babies born
before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a
condition that affects the retina, the tissue at the back of the eye. The
retina detects light and sends signals to the brain, allowing you to see.
Unwanted blood vessels grow on the baby’s retina due to ROP. These blood
vessels can later cause serious eye and vision problems. Sometimes,
immediate treatment is required to avoid blindness. If not treated promptly,
the child may suffer from severe permanent vision loss or even go
blind. Most babies with ROP normally see for their age.
Vision is only threatened when ROP progresses to the most severe
stages. Fortunately, the majority of ROP resolves without causing vision loss.
The most important factors in preventing ROP-related vision loss are
effective screening and timely treatment (when indicated. Birth weight and
gestational age are the most critical risk factors for developing severe ROP.
Other factors associated with the presence of ROP include anemia, poor weight
gain, blood transfusion, respiratory distress, breathing
difficulties and the infant’s overall health. There is active
research into the correlation between levels of growth factors in the
blood and ROP. Close monitoring has reduced the impact of oxygen use as a
risk factor for developing ROP. Light levels do not affect the severity of ROP.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment